Up next

CEOs, Senior Executives Highlight Mfg Expansions at the DCAT Member Company Announcement Forum

CEOs and senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week. Manufacturing expansions for peptides, biomanufacturing, and sterile manufacturing led the news. 

CEOs and senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week. Manufacturing expansions for peptides, biomanufacturing, and sterile manufacturing led the news. 

By Patricia Van Arnum, Editorial Director, DCAT, [email protected]

CEO and senior executives from DCAT Member Companies highlighted their companies major news at the DCAT Member Company Announcement Forum at DCAT Week, the flagship event of the Drug, Chemical & Associated Technologies Association (DCAT). Companies reported the latest in expansion plans across the bio/pharmaceutical manufacturing value chain: from drug substances (small-molecules and biologics) to drug products (solid dosage and injectable product forms). In all, 20 companies took to the podium to make their announcements. The program kicked off DCAT Week on Monday March 17th, 2025.

Led by the success of glucagon-like peptide-1 (GLP-1) agonists, a number of companies reported expansions in peptide development and manufacturing, punctuated by CordenPharma’s more than $1-billion expansion plan. Other companies proceeding with peptide expansions, at various scales, included BioDuro, Neuland Laboratories, SK pharmteco, and Axplora (through an expansion on large-scale high-performance liquid chromatography (HPLC) and continuous chromatography for API purification, including peptides).

Other companies are proceeding with expansions in fine-chemicals, small-molecule active pharmaceutical ingredients (APIs), either general expansions or capabilities for specialized products, such as antibody drug conjugates or other conjugated products. These companies included SK pharmteco, BioDuro, Procos, Esteve, Lonza, and Lacamas Laboratories.

Multi-billion dollar expansions in biologics (drug substance) were also a highlight of the Member Company Announcement Forum with FUJIFILM Diosynth Biotechnologies and Lonza providing updates of their large-scale projects. Although not at the same scale, Thermo Fisher Scientific provided an update of its biomanufacturing expansions. For early-stage research, Bio X Cell, a producer of functional in vivo antibodies for translational research, highlighted its new distribution center in China. Also, Avantor outlined a large expansion in its hydration capabilities to support bioprocessing and other processes.   

On the drug-product side, Thermo Fisher Scientific provided details of its expansions in fill-finish and sterile manufacturing as did other companies, which reflected a truly global reach: Symbiotec Pharmalab (India), Boston Oncology (Saudi Arabia), RV Group (Vietnam), JGL (Croatia), and Upperton Pharma Solutions (UK). Also, Ursatec provided an update on its expansion strategy for the US market for its preservative-free drug-delivery systems.

One announcement that stood out for its uniqueness from a technology view was from the CMDO Bora Pharmaceuticals, which outlined how the company was using and plans to use artificial intelligence in its operations.

Details of each company’s announcement can be found below. 

Recent Feature Articles

Innovation & Pharma: The Molecules & Companies

By
How truly innovative is the bio/pharma industry? What products, modalities, and companies are behind that innovation? Looking at “first-in-class” new drug approvals, defined as drugs with new mechanisms of action over existing drugs, reveals an interesting picture.

FDA Launches Pilot To Expedite INDs

By
FDA has launched a pilot program to expedite review of investigational new drug (IND) filings with applications for the pilot due by October 30. It is part of the agency’s Operation TrialBlazer initiative, designed to make the US more competitive in early-stage research.

Beyond ADCs: Next-Generation Drug Conjugates 

By
Antibody drug conjugates (ADCs) continue to be a strong growth area, but next-generation drug conjugates, encompassing oligonucleotides, peptides, and other small-molecule payloads, are on the rise.

Sandoz Maps Out Ambitious Biosimilars Growth Plan

By
Sandoz has rolled out a plan to increase its biosimilars portfolio to more than 100 biosimilars, including generic GLP-1’s by 2040, increase manufacturing capacity, and more than double its net sales by 2035.